Lantern Pharma Inc.
LTRN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | 0.09 | -0.05 | 0.25 |
| FCF Yield | -11.55% | -11.46% | -11.55% | -14.14% |
| EV / EBITDA | -6.05 | -6.71 | -4.61 | -6.12 |
| Quality | ||||
| ROIC | -36.35% | -28.13% | -27.51% | -19.12% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.09 | 0.91 | 0.96 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 10.04% | -10.11% | 28.83% | -7.51% |
| Safety | ||||
| Net Debt / EBITDA | 1.27 | 1.30 | 1.23 | 1.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -95,035.84 | -81,163.69 | -7,317.49 | -6,401.06 |